InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $8.150 0.11 (1.33%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$411 Commitments Test Entity - Second Quarter Report 30 Jan 2007 10:02AM $0.815 $8.150 risen by 900%
$411 Receives approval to begin Phase III trials 24 Jan 2007 8:30AM $0.800 $8.150 risen by 918.75%
$411 Open Briefing.Clinuvel CEO Updates Outlook 14 Nov 2006 11:20AM $0.495 $8.150 risen by 1,546.46%
$411 Commitments Test Entity - First Quarter Report 24 Oct 2006 1:44PM $0.405 $8.150 risen by 1,912.35%
$411 Prospectus for A$25m Rights issue 3 Oct 2006 10:35AM $0.431 $8.150 risen by 1,793.15%
$411 A$25m capital raising 20 Sep 2006 4:24PM $0.416 $8.150 risen by 1,858.19%
$411 Preliminary Final Report & Full Year Accounts 13 Sep 2006 2:09PM $0.402 $8.150 risen by 1,928.37%
$411 GAA ann Acquisition of EpiPharm dermatology 12 Sep 2006 8:42AM $0.411 $8.150 risen by 1,881.04%
$411 To commence CUV1647 Phase II trial for Erythropoiet 5 Sep 2006 11:36AM $0.383 $8.150 risen by 2,029.61%
$411 Files Patent Application for CUV1647 1 Sep 2006 10:20AM $0.388 $8.150 risen by 2,003.23%
$411 Clinuvel Files New Patent Application for CUV1647 29 Aug 2006 1:17PM $0.364 $8.150 risen by 2,141.47%
$411 Open Briefing Clinuvel PLE Phase II Final Results and Update 28 Aug 2006 10:43AM $0.344 $8.150 risen by 2,266.43%
$411 Clinuvel successfully meets endpoints in Phase II trial 28 Aug 2006 10:23AM $0.344 $8.150 risen by 2,266.43%
$411 Commitments Test Entity - Fourth Quarter Report 28 Jul 2006 12:18PM $0.325 $8.150 risen by 2,405.38%
$411 Meets primary endpoints in Phase II Trial 16 Jun 2006 9:59AM $0.349 $8.150 risen by 2,233.91%
$411 Private Placement raises A$5.0 million 1 May 2006 11:35AM $0.440 $8.150 risen by 1,751.85%
$411 Commitments Test Entity - Third Quarter Report 28 Apr 2006 4:00PM $0.431 $8.150 risen by 1,793.15%
$411 Positive interim results Phase 2 trial on Polymorphous Light 18 Apr 2006 9:31AM $0.383 $8.150 risen by 2,029.61%
$411 Half Yearly Report & Half Year Accounts 15 Mar 2006 9:06AM $0.340 $8.150 risen by 2,299.88%
$411 Pharmacokinetic Trials Begin in Adelaide 28 Feb 2006 1:50PM $0.297 $8.150 risen by 2,647.81%

851 - 870 of 870 results

Page 35 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.